ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

F182112 single-agent

Its studies are mostly in Multiple Myeloma, led by Lunan Pharmaceutical Group.

Furthest: phase 3, since May 6, 20261 company-led study, 1 open or runningNext primary completion: Jan 25, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lunan Pharmaceutical Group11 open or runningphase 3since May 6, 2026May 6, 2026Jan 25, 2029phase 3 · NCT07579234

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2026First study: phase 3 study in RecurrenceFirst studyNCT07579234 · 261 planned · China

Ahead

  1. Jan 25, 2029Primary completion: phase 3 study in RecurrenceNCT07579234

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07579234Recurrence · China3RecruitingJan 25, 2029261

How it is read

Names in the registry

  • “F182112 single-agent”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.